Spectrum Of Activity
600 mg PO q24h
Take at bedtime, without food. Food may increase serum concentration, which can lead to elevated risk of adverse events.No renal dose adjustment
Safety and efficacy in pediatric patients <3m of age or <3.5 kg of BW have not been established
BW 3.5-5 kg 100 mg PO q24h
BW 5-7.5 kg 150 mg PO q24h
BW 7.5-15 kg 200 mg PO q24h
BW 15-20 kg 250 mg PO q24h
BW 20-25 kg 300 mg PO q24h
BW 25-32.5 kg 350 mg PO q24h
BW 32.5-40 kg 400 mg PO q24h
BW >40 kg 600 mg PO q24hNo renal dose adjustment
Mild or moderate hepatic impairment No dose adjustment
Severe hepatic impairment No data
Treatment of HIV infection.
Indicated for use as a NNRTI agent as part of a 3-drug combination regimen.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Serum cholesterol and serum triglycerides raised
Increased liver enzymes
Prolonged QT interval
Torsades de pointes
Paritaprevir - increased efavirenz plasma concentrations, elevated liver enzymes
St John's wort - increased risk of antiretroviral resistance and treatment
QT interval prolonging drugs
Multiple drug-drug interactions
Antimicrobial class: Antiretroviral agent, Non-nucleoside reverse transcriptase inhibitor
Pregnancy category: D
Average serum half life: 40-55 hours
Urine penetration: Therapeutic
CSF penetration: Therapeutic
Precautions: Monotherapy should not be used as viral cross-resistance may develop if used alone or added as a sole agent to a failing regimen.
Liver function monitoring recommended for all patients.
Not recommended in patients with moderate to severe hepatic impairment.
Late-onset neurotoxicity may occur months to years after beginning therapy, especially in patients with CYP2B6 genetic polymorphisms associated with increased efavirenz levels; discontinuation may be warranted.
Immediate medical evaluation recommended for serious psychiatric symptoms.
Negative pregnancy test warranted prior to therapy initiation.